Medigene AG (ETR:MDG1)

Market Cap	1.97M
Revenue (ttm)	7.45M
Net Income (ttm)	-15.93M
Shares Out	14.74M
EPS (ttm)	-1.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	189,470
Average Volume	54,064
Open	0.1555
Previous Close	0.1845
Day's Range	0.0782 - 0.1595
52-Week Range	0.0782 - 2.9800
Beta	1.17
RSI	23.20
Earnings Date	Aug 15, 2025

About Medigene AG

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications. The company also develops MDG2011, MDG2021, MDG2012, MDG20XX, and MDG10xx to treat multiple solid tumors. It has a strategic partnership with BioNTech to develop TCRbased immu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 76
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: MDG1

Financial Performance

In 2023, Medigene AG's revenue was 6.03 million, a decrease of -80.69% compared to the previous year's 31.25 million. Losses were -16.18 million, 94.2% more than in 2022.